Evidence map›Paper›PMID 32152478›Full record

ReviewNature reviews. Gastroenterology & hepatology2020

Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Judith Aron-Wisnewsky, Chloé Vigliotti, Julia Witjes, Phuong Le, Adriaan G Holleboom, Joanne Verheij, Max Nieuwdorp, Karine Clément

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Gastroenterology & hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 629 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
629citing papers in PubMed, 8 pooled it
78.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

629 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,010 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Effects ofGut microbes · 2026
    Article
  13. Article
  14. Article
  15. Gut microbes · 2026
    Article
  16. Review
  17. Colonic metabolomic and transcriptomic alterations in a mouse model of metabolic syndrome.American journal of physiology. Gastrointestinal and liver physiology · 2026
    Article
  18. Article
  19. Review
  20. Review

569 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Judith Aron-Wisnewsky *Sorbonne Université, INSERM, Nutriomics Research Unit, Paris, France.
Chloé Vigliotti *Sorbonne Université, INSERM, Nutriomics Research Unit, Paris, France.
Julia WitjesAmsterdam UMC, location AMC, Dept of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands.
Phuong LeSorbonne Université, INSERM, Nutriomics Research Unit, Paris, France.
Adriaan G HolleboomAmsterdam UMC, location AMC, Dept of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands.
Joanne VerheijAmsterdam UMC, location AMC, Dept of Pathology, University of Amsterdam, Amsterdam, The Netherlands.
Max NieuwdorpAmsterdam UMC, location AMC, Dept of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands.
Karine ClémentSorbonne Université, INSERM, Nutriomics Research Unit, Paris, France. karine.clement@aphp.fr.ORCID http://orcid.org/0000-0002-2489-3355
Inserm · FRAmsterdam University Medical Centers · NLAmsterdam Neuroscience · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gut microbiota dysbiosis has been repeatedly observed in obesity and type 2 diabetes mellitus, two metabolic diseases strongly intertwined with non-alcoholic fatty liver disease (NAFLD). Animal studies have demonstrated a potential causal role of gut microbiota in NAFLD. Human studies have started to describe microbiota alterations in NAFLD and have found a few consistent microbiome signatures discriminating healthy individuals from those with NAFLD, non-alcoholic steatohepatitis or cirrhosis. However, patients with NAFLD often present with obesity and/or insulin resistance and type 2 diabetes mellitus, and these metabolic confounding factors for dysbiosis have not always been considered. Patients with different NAFLD severity stages often present with heterogeneous lesions and variable demographic characteristics (including age, sex and ethnicity), which are known to affect the gut microbiome and have been overlooked in most studies. Finally, multiple gut microbiome sequencing tools and NAFLD diagnostic methods have been used across studies that could account for discrepant microbiome signatures. This Review provides a broad insight into microbiome signatures for human NAFLD and explores issues with disentangling these signatures from underlying metabolic disorders. More advanced metagenomics and multi-omics studies using system biology approaches are needed to improve microbiome biomarkers.

Indexed as

AnimalsDiabetes Mellitus, Type 2Digestive System DiseasesDysbiosisGastrointestinal MicrobiomeHumansNon-alcoholic Fatty Liver DiseaseObesitySignal Transduction

Identifiers

PMID32152478
OpenAlexW3009231580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.